Curetis Raised Additional €14.5M to Diagnose Severe Infectious Diseases

27/11/2014 - 2 minutes

Curetis AG, a developer of next-level molecular diagnostic solutions, has closed a EUR 14.5 million extension of its Series B financing round, which was originally led by HBM Partners in April 2013.

Curetis is a young, dynamic and creative molecular diagnostics company. They are specialized in the diagnosis of severe infectious diseases in hospitalized patients. The company helps to combat infections effectively and detect antibiotic resistance at an early stage.

New investors Qiagen and LSP Health Economics Fund (LSP-HEF) participated in the round with a commitment of €7 million, joining several existing investors that together committed €7.5 million. The existing investors included Aeris Capital, BioMed Invest, CD Venture, Forbion Capital, HBM Partners, Life Science Partners, Roche Venture Fund, Curetis management, a trustee pool of Curetis employees, and private angel investors.

The European market introduction of both the Unyvero P50 Pneumonia and i60 Implant and Tissue Infection applications, allowing a faster and better diagnosis of life-threatening infectious diseases, has shown increasing traction.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
Do you want to remove this advert? Become a member!
Do you want to remove this advert? Become a member!